BCAL DIAGNOSTICS LIMITED — Capital/Financing Update 2026

Mar 25, 2026

==> picture [152 x 46] intentionally omitted <==

ASX Announcement

26 March 2026

==> picture [182 x 47] intentionally omitted <==

BCAL accelerates national commercial rollout of Avantect pancreatic and ovarian early detection blood tests

Highlights

• Avantect Pancreatic and Ovarian blood tests are now available through selected Sonic Healthcare pathology collection centres in New South Wales, Queensland, and Victoria; a new agreement with Healius Pathology Network provides national access.

• Follows launch of Avantect tests in January at the Sydney Breast Clinic.

• Expands existing collaboration with Sonic Healthcare to advance access to BCAL’s bloodbased cancer diagnostic test, BREASTEST plus .

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, is accelerating the commercial roll out of Avantect Pancreatic and Ovarian blood tests, with tests now available through selected Sonic Healthcare pathology collection centres in New South Wales, Victoria and Queensland, and nationally through a new agreement with Healius Pathology Network.

National roll out follows the initial launch of the Avantect tests in January 2026 through Sydney Breast Clinic.

Avantect is a cell-free DNA-based blood test designed to support the early detection of pancreatic and ovarian cancers in patients identified as being at elevated risk. The latest generation of the Avantect test incorporates advances in genomic and epigenomic analysis combined with machine learning to provide valuable additional information for doctors and patients.

BCAL CEO Shane Ryan said, “ We are incredibly excited to make Avantect products available nationally through our collaboration with Sonic and Healius, two of Australia’s leading pathology providers, accelerating the commercial rollout of these important tests. Clinicians can now begin ordering the tests for their patients using an established national collection network.

We know that early detection improves clinical outcomes by identifying cancers at a stage where treatment options can be more effective.

This initiative builds on our existing collaboration with Sonic Healthcare, supporting broader patient access to our growing portfolio of blood-based cancer diagnostics, including BREASTEST plus .”

For further information, visit earlydetection.com.au

This announcement has been approved for release by the Board of BCAL.

ENDS

==> picture [152 x 46] intentionally omitted <==

For further information:

Shane Ryan Jayne Shaw Chief Executive Officer Executive Chair Sryan@bcaldiagnostics.com Jshaw@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST plus ™ as a ‘rule-out’ test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST plus ™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: htps://www.bcaldiagnostcs.com/ or contact info@bcaldiagnostcs.com.